Gemäß den neuesten Finanzberichten von Abbott Laboratories betragen die Gesamtverbindlichkeiten des Unternehmens €27.89 Milliarden Euro. Die Gesamtverbindlichkeiten eines Unternehmens sind die Summe aller kurzfristigen und langfristigen Schulden und Verpflichtungen.
Jahr | Gesamtverbindlichkeiten | Veränderung |
---|---|---|
2024-12-31 | €32.20 Mrd. | 3.53% |
2023-12-31 | €31.10 Mrd. | -11.1% |
2022-12-31 | €34.99 Mrd. | 1.16% |
2021-12-31 | €34.58 Mrd. | 7.58% |
2020-12-31 | €32.15 Mrd. | -1.56% |
2019-12-31 | €32.65 Mrd. | 2.5% |
2018-12-31 | €31.86 Mrd. | -15.33% |
2017-12-31 | €37.63 Mrd. | 23.89% |
2016-12-31 | €30.37 Mrd. | 66.71% |
2015-12-31 | €18.21 Mrd. | 13.24% |
2014-12-31 | €16.08 Mrd. | 25.63% |
2013-12-31 | €12.80 Mrd. | -58.09% |
2012-12-31 | €30.55 Mrd. | 11% |
2011-12-31 | €27.52 Mrd. | -3.15% |
2010-12-31 | €28.42 Mrd. | 37.97% |
2009-12-31 | €20.60 Mrd. | 15.67% |
2008-12-31 | €17.81 Mrd. | 18.56% |
2007-12-31 | €15.02 Mrd. | -10.4% |
2006-12-31 | €16.76 Mrd. | 34.88% |
2005-12-31 | €12.43 Mrd. | 16.77% |
2004-12-31 | €10.64 Mrd. | 3.37% |
2003-12-31 | €10.29 Mrd. | -20.8% |
2002-12-31 | €13.00 Mrd. | -19.33% |
2001-12-31 | €16.12 Mrd. |
Unternehmen | Gesamtverbindlichkeiten | DifferenzDiff. | Land |
---|---|---|---|
![]() Johnson & Johnson JNJ | €99.53 Mrd. | 256.85% | 🇺🇸 USA |
![]() Pfizer PFE | €101.10 Mrd. | 262.50% | 🇺🇸 USA |
![]() Thermo Fisher Scientific TMO | €42.68 Mrd. | 53.03% | 🇺🇸 USA |
![]() Hologic HOLX | €3.38 Mrd. | -87.88% | 🇺🇸 USA |
![]() Medtronic MDT | €34.76 Mrd. | 24.62% | 🇮🇪 Ireland |
![]() Bristol-Myers Squibb BMY | €64.57 Mrd. | 131.53% | 🇺🇸 USA |
![]() Boston Scientific BSX | €15.23 Mrd. | -45.36% | 🇺🇸 USA |
![]() AstraZeneca AZN | €56.08 Mrd. | 101.09% | 🇬🇧 UK |
![]() Novartis NVS | €52.96 Mrd. | 89.87% | 🇨🇭 Switzerland |
![]() GlaxoSmithKline GSK | €52.43 Mrd. | 87.98% | 🇬🇧 UK |